Asa Hatami

Asa Hatami has a diverse work experience in the field of neuroscience and biology. Asa is currently working as a Principal Scientist - CNS Biology at Scribe Therapeutics since May 2023. Prior to this role, they worked at Sangamo Therapeutics, Inc. where they held several positions including Senior Scientist from February 2023 to May 2023, Scientist III - Neuroscience from February 2021 to February 2023, and Scientist II - Discovery and Translational Research from September 2018 to February 2021.

Before joining Sangamo Therapeutics, Inc., Asa Hatami worked at UCLA Department of Neurology as a Postdoctoral Scholar. Asa held this position twice, from December 2013 to September 2016 and from March 2015 to November 2015. During their time at UCLA Department of Neurology, they conducted various research projects related to traumatic brain injury and Parkinson's disease.

Asa Hatami also has experience as a Graduate Student Researcher at UC Irvine Department of Molecular Biology and Biochemistry from September 2008 to December 2013. Their research focused on protein misfolding and aggregation in Alzheimer's disease.

Additionally, they worked as a Researcher at UCLA Semel Institute for Neuroscience and Human Behavior from August 2006 to August 2008. In this role, they conducted research on the effects of alpha-synuclein overexpression on synaptic plasticity and oxidative stress in a mouse model of Parkinson's disease.

Overall, Asa Hatami has a strong background in neuroscience and biology, with expertise in preclinical investigations, protein misfolding, and neurodegenerative diseases such as Alzheimer's and Parkinson's.

Asa Hatami attended UCLA from 2002 to 2006, where they earned a Bachelor of Science degree in Neuroscience. Asa then pursued further education at UC Irvine from 2008 to 2013, obtaining a Doctor of Philosophy (Ph.D.) in Molecular Biology and Biochemistry.